RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @Dr_Khan: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. A Secondary Analysis of the S…
RT @Dr_Khan: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. A Secondary Analysis of the S…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @Dr_Khan: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. A Secondary Analysis of the S…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @fjavesc: @diabeteSEEN @moreno_perez_o @rebecareyesgar1 @estebanjodar
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. A Secondary Analysis of the SCORED Trial. Clinical Journal of the American Society of Nephrology. https://t.co/5FFibPBy2s https://t.co/fm3F7pN1J6
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. A Secondary Analysis of the SCORED Trial. Clinical Journal of the American Society of Nephrology. https://t.co/5FFibPBy2s
@diabeteSEEN @moreno_perez_o @rebecareyesgar1 @estebanjodar
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albu... : Clinical Journal of the American Society of Nephrology https://t.co/SMby0jlb3x
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sot…
Sotagliflozin is a dual SGLT1 and 2 inhibitor that has cardiovascular benefits. Using laboratory eGFR data, this study found sotagliflozin reduced the risk of kidney and cardiorenal composite end points in patients with type 2 diabetes and CKD https://t.co
RT @abdelhamed012: Sotagliflozin and Kidney Outcomes, Kidney Function, and... : Clinical Journal of the American Society of Nephrology http…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
RT @joeMD77: Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placeb…
Sotagliflozina, eventos renales, albuminuria en nefropatia diabética. -SCORED TRIAL- 🟡10,584 👫🏻 c/DM2 🟡Sotagliflozina v placebo 🟢Reducción 38% de MAKE (TFG <15, diálisis, trasplante) 🟢Reducción 23% evento cardio renal y muerte por CV/ renal CJASN 2024
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
Sotagliflozin and Kidney Outcomes, Kidney Function, and... : Clinical Journal of the American Society of Nephrology https://t.co/x1kidBAOlD
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @AryMartnez16: Sotagliflozina ❤️
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
Sotagliflozin and Kidney Outcomes, Kidney Function, and... : Clinical Journal of the American Society of Nephrology https://t.co/SMby0jlb3x
Sotagliflozina ❤️
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…